This statistic shows the amount of registrations of newly diagnosed cases of skin cancer in England in 2022, by age group and gender. Almost *** thousand new cases were recorded among men aged 75 to 79 years of age. It should be noted that the number of people in England in each age group varies and is therefore not necessarily a reflection of susceptibility to skin cancer.

In 2021, around 13,883 people aged 70 to 74 years were diagnosed with melanoma of the skin or another non-epithelial skin cancer, the highest number of any age group. This statistic shows the number of new skin cancer cases in the U.S. in 2021, by age.

Legacy unique identifier: P00653

In the years 2016 to 2020, over ** percent of patients diagnosed with melanoma of the skin in England aged between 15 and 44 years of age would survive for at least one year, while patients this age had a five-year survival rate of nearly ** percent. The survival rates for melanoma of the skin did generally fall if the patient was older when diagnosed.

Supplementary Figure 1. Cutaneous Melanoma Age-adjusted Incidence Trends (2012-2021) Supplementary Figure 2. Cutaneous Melanoma Age-adjusted Mortality Trends (2013-2022) Journal of the American Academy of Dermatology

This data was taken from the R `lattice' package. The data is described in the package as follows: These data from the Connecticut Tumor Registry present age-adjusted numbers of melanoma skin-cancer incidences per 100,000 people in Connecticut for the years from 1936 to 1972. Format: A csv file has 37 observations on the following 2 variables. year: years 1936 to 1972. incidence: rate of melanoma cancer per 100,000 population.

This csv reports melanoma registration rates, per 100,000 population, by age. Age is grouped in 5 year segments (eg 0–4 years old, 5–9 years old). New Zealand and Australia have the world’s highest rates of melanoma, the most serious type of skin cancer. Melanoma is mainly caused by exposure to ultraviolet (UV) light, usually from the sun. New Zealand has naturally high UV levels, especially during summer.
The risk of developing melanoma is affected by factors such as skin colour and type, family history, and the amount of sun exposure. Melanoma can affect people at any age, but the chance of developing a melanoma increases with age. We report on age-standardised rates of melanoma to account for the increasing proportion of older people in our population. Our data on melanoma registrations come from the New Zealand Cancer Registry and the Ministry of Health's Mortality Collection. The passing of the Cancer Registry Act 1993 and Cancer Registry Regulations 1994 led to significant improvements in data quality and coverage (Ministry of Health, 2013). A sharp increase in registrations after 1993 is likely to have been related to these legislative and regulatory changes; for this reason we have only analysed data from 1996. 2014–15 data are provisional and subject to change. More information on this dataset and how it relates to our environmental reporting indicators and topics can be found in the attached data quality pdf.

In 2022, Australia had the fourth-highest total number of skin cancer cases worldwide and the highest age-standardized rate, with roughly 37 cases of skin cancer per 100,000 population. The graph illustrates the rate of skin cancer in the countries with the highest skin cancer rates worldwide in 2022.

Skin Cancer Market Outlook

The global skin cancer market size was valued at approximately USD 2.5 billion in 2023 and is projected to reach around USD 4.85 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2032. The market is experiencing steady growth due to factors such as increasing incidence rates of skin cancer, advancements in diagnostic and treatment technologies, and heightened awareness of skin cancer prevention and early detection. As a non-negligible public health concern, skin cancer's rising prevalence continues to drive the demand for effective diagnostic and treatment options, thereby propelling the market forward.

A significant growth factor for the skin cancer market is the increasing incidence of skin cancer cases worldwide. Over the past few years, there has been a noticeable surge in the number of skin cancer diagnoses, which can be attributed to factors such as heightened exposure to ultraviolet (UV) radiation from the sun and tanning beds, aging populations, and cultural trends favoring tanned skin. Additionally, genetic predispositions and the depletion of the ozone layer have further exacerbated the exposure risks. Public health initiatives have increased awareness around protective measures, yet the rise in cases continues, fueling the demand for more advanced diagnostic and treatment solutions.

Technological advancements in the field of dermatology are also significantly contributing to the growth of the skin cancer market. Innovations in diagnostic tools, such as dermatoscopy and advanced imaging solutions, have improved the accuracy and early detection rates of skin cancer. These technologies allow for non-invasive, cost-effective, and efficient identification of skin abnormalities, which are crucial for early intervention and improved patient outcomes. Furthermore, developments in treatment modalities, including targeted therapy and immunotherapy, offer more personalized and effective treatment options, enhancing the demand for cutting-edge solutions in the market.

Increased awareness and initiatives for early detection and prevention are pivotal drivers of market growth. Government bodies and non-profit organizations around the world have launched various campaigns to educate the public on the dangers of UV exposure and the importance of regular skin examinations. These initiatives have led to a rise in the number of individuals seeking medical advice and undergoing skin checks, thereby increasing the demand for dermatological healthcare services. Moreover, as people become more informed about the potential risks and signs of skin cancer, the market for diagnostic and preventive healthcare is expected to grow steadily.

The regional outlook of the skin cancer market indicates significant growth potential across various geographical areas. North America holds a substantial share of the market, driven by a high prevalence of skin cancer, advanced healthcare infrastructure, and robust investment in research and development. Europe follows closely with similar characteristics, including a strong emphasis on research and preventive healthcare measures. The Asia Pacific region is anticipated to exhibit the highest CAGR over the forecast period due to increasing healthcare awareness, rising disposable income, and the growing prevalence of skin cancer in countries such as Australia. Conversely, regions like Latin America, the Middle East, and Africa are expected to witness moderate growth, primarily due to lower awareness levels and limited access to advanced healthcare facilities.

Basal Cell Carcinoma Drug development is a crucial aspect of the skin cancer treatment landscape. As the most common type of skin cancer, basal cell carcinoma (BCC) often requires targeted therapeutic interventions to manage effectively. Recent advancements in pharmacology have led to the creation of innovative drugs that specifically target the molecular pathways involved in BCC proliferation. These drugs offer new hope for patients, particularly those with advanced or recurrent BCC, by providing more effective treatment options with fewer side effects compared to traditional therapies. The ongoing research and development in this area are expected to significantly impact the market, offering patients improved outcomes and expanding the arsenal of available treatments.

Type Analysis

The skin cancer market is segmented by type into basal cell carcinoma, squamous cell carcinoma, and melanoma, each repres

The Skin Cancer Therapeutics Market is Segmented by Disease Type (Melanoma, Basal Cell Carcinoma, and More), Treatment Modality (Surgery, Chemotherapy, Immunotherapy, and More), End User (Hospitals, Dermatology Clinics, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Sizes and Forecasts are Provided in Terms of Value (USD).

In the years 2018, 2019, and 2021 the probability that a man in the U.S. aged 65 to 84 years would develop melanoma of the skin was *** percent. This statistic shows the probability of developing melanoma skin cancer in the U.S. in 2018, 2019 and 2021, by age and gender.

Snapshot img

Non-Melanoma Skin Cancer Market Size 2024-2028

The non-melanoma skin cancer market size is forecast to increase by USD 136.9 million at a CAGR of 4.5% between 2023 and 2028.

The non-melanoma skin cancer (NMSC) market is experiencing significant growth due to the increasing incidence of this type of cancer. NMSC is the most common form of cancer, with over three million cases diagnosed annually worldwide. The market is facing a challenge due to the lack of drugs in the pipeline for NMSC treatment. This trend is expected to continue, as current treatments such as surgical excision and Mohs micrographic surgery have limitations and may leave scars or require multiple procedures. Healthcare services are playing a critical role in addressing this issue by improving early detection, offering advanced treatment options, and providing patient support throughout the recovery process. Additionally, the aging population and rising awareness about cosmetic skin care are contributing to the market's growth. The market analysis report provides an in-depth analysis of these trends and growth factors, offering valuable insights for stakeholders In the healthcare industry.

What will be the Size of the Non-Melanoma Skin Cancer Market During the Forecast Period?

Request Free Sample

The market encompasses a range of conditions, including basal cell carcinoma and squamous cell carcinoma. These forms of cancer are primarily caused by sun exposure, resulting in symptoms such as scaly surfaces, red patches, sores, moles, or warts. Treatment modalities include surgery, radiation therapy, photodynamic therapy, topical therapies, cryosurgery, and electrodesiccation. Mohs surgery, a specialized form of surgery, is increasingly utilized for high-risk occurrences due to its ability to preserve healthy tissue.
Advanced treatments, such as Vismodegib, offer promising alternatives for patients with recurrent or metastatic disease. The market is driven by the increasing prevalence of sun exposure-related injuries and the growing aging population. Despite advancements in treatment options, the risk of recurrence remains a significant concern, necessitating ongoing research and innovation.

How is this Non-Melanoma Skin Cancer Industry segmented and which is the largest segment?

The non-melanoma skin cancer industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Type

  BCC
  SCC


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    China
    Japan


  Rest of World (ROW)

By Type Insights

The bcc segment is estimated to witness significant growth during the forecast period.

Non-Melanoma Skin Cancer (NMSC), primarily comprised of Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC), accounts for a significant portion of cancer occurrences worldwide. BCC, responsible for approximately 80% of NMSC, has seen an annual growth rate of 2% In the US and 5% in Europe. In the Asia Pacific region, Australia holds the highest incidence of BCC among individuals aged 70. Despite a low mortality rate of approximately 0.05%, BCCs can result in disfiguring body alterations. Surgical treatments, including Mohs surgery, cryosurgery, and electrodesiccation, are common interventions. Radiation therapy, photodynamic therapy, and topical therapies also serve as alternative treatment methods.

Get a glance at the Non-Melanoma Skin Cancer Industry report of share of various segments Request Free Sample

The BCC segment was valued at USD 410.20 million in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 29% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

Non-Melanoma Skin Cancer (NMSC), comprised primarily of Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC), is a significant health concern In the US, accounting for approximately 35-45% of all cancers among Caucasians. NMSC is the most common cancer type In the US, with BCC being the most prevalent skin cancer subtype. Treatment modalities for NMSC include surgery, radiation therapy, photodynamic therapy, topical therapies, cryosurgery, electrodesiccation, Mohs surgery, Vismodegib for advanced cases, and chemotherapy for metastasis. Risk factors for NMSC include sun exposure, sunburns, radiation exposure, inflammation, injury, and the presence of skin growths such as bumps, moles, red patches, sores, moles, warts, and recurrence.

Market Dynamics

Our researchers analyzed the data wit

IntroductionNon - melanoma skin cancer (NMSC) is a widespread malignant neoplasm affecting the skin globally. In China, over the past 30 years, the prevalence and incidence of NMSC have changed significantly, yet mortality rate (MR) data is scarce. The aim is to assess the MR data of NMSC patients worldwide from 1992 to 2021, analyze its temporal trends, and provide valuable epidemiological information for future prevention and management strategies of NMSC.MethodsUsing data from the Global Burden of Disease Study 2021 (GBD 2021), we analyzed crude mortality rate (CMR), age-standardized mortality rate (ASMR), and sex- and age-specific mortality trends, with temporal patterns assessed through longitudinal comparisons.ResultsThe MR for NMSC has shown an upward trend globally. From 1992 to 2021, both the CMR and ASMR for NMSC have increased substantially. The global ASMR has risen by approximately 30% during this period. Males have a higher ASMR compared to females, and the elderly population exhibits an accelerated and elevated ASMR trend for NMSC. In China, the mortality of NMSC is on the rise, with the current male MR exceeding that of females. Although the ASMR is projected to decline by 2030, the number of mortality cases is expected to increase, especially among males. The MR for NMSC shows a significant bias towards the elderly demographic.DiscussionThe increasing mortality of NMSC, both globally and in China, highlights the importance of effective prevention and management strategies. In addition to implementing prevention and intervention measures in susceptible populations, it is crucial to establish a screening framework for NMSC to detect minor symptoms in a timely manner. This will help in early diagnosis and potentially reduce the mortality rate associated with NMSC. Thank you for your editorial support.

This is historical data. The update frequency has been set to "Static Data" and is here for historic value. Updated 8/14/2024.

Definition of "All Cancer Sites": ICD-O-3 Topography (Site) Codes C00.0 – C80.9 with histology codes including all invasive cancers of all sites except basal and squamous cell skin cancers, and in situ cancer cases of the urinary bladder. Rates are per 100,000 population and are age-adjusted to 2000 U.S. standard population. Rates based on case counts of 1-15 are suppressed per DHMH/MCR Data Use Policy and Procedures.

Skin Cancer Diagnostics Market Outlook

The global skin cancer diagnostics market is witnessing considerable expansion, with a market size estimated at USD 4 billion in 2023. It is projected to reach approximately USD 8.3 billion by 2032, growing at a robust CAGR of 8.7% during the forecast period. This growth is driven by increasing awareness of skin cancer, advancements in diagnostic technologies, and a rising prevalence of skin cancer worldwide. The combination of these elements is propelling the market forward, making it a critical area of focus within the broader healthcare diagnostics industry.

One of the primary growth factors in the skin cancer diagnostics market is the increasing incidence of skin cancer globally. Skin cancer is the most common malignancy, with millions of new cases diagnosed each year. Factors such as heightened UV exposure, the depletion of the ozone layer, and lifestyle changes contribute significantly to the rising number of skin cancer cases. Consequently, there is a growing demand for early diagnostic tools that can effectively detect melanoma and non-melanoma skin cancers, thereby driving market growth. Health organizations and governments worldwide are investing in awareness campaigns and screening programs, further boosting the demand for advanced diagnostic technologies.

Technological advancements in diagnostic tools also play a crucial role in the market's expansion. The evolution of diagnostic technologies, including molecular diagnostics, digital pathology, and imaging techniques, has revolutionized the landscape of skin cancer detection. These advanced technologies offer higher accuracy, faster results, and non-invasive procedures, making them highly sought after in clinical settings. The integration of artificial intelligence and machine learning in diagnostic processes has also enhanced the precision of skin cancer detection, thereby encouraging healthcare providers to adopt these innovative solutions. This wave of technological innovation is a vital driver of market growth.

Increasing healthcare expenditure and the expansion of health insurance coverage further support the growth of the skin cancer diagnostics market. As more people gain access to healthcare services, the demand for diagnostic procedures grows. This is particularly significant in emerging markets, where healthcare infrastructure is rapidly developing. Furthermore, as the population ages, the incidence of skin cancer is expected to rise, given that older individuals are at higher risk. This demographic shift underscores the need for efficient diagnostic solutions, thereby fueling market expansion. The interplay of these factors creates a favorable environment for the growth of the skin cancer diagnostics market.

In parallel with the advancements in skin cancer diagnostics, the field of Oral Cancer Diagnostic is also experiencing significant progress. The increasing incidence of oral cancer has prompted the development of advanced diagnostic tools that can facilitate early detection and improve patient outcomes. Technologies such as fluorescence visualization, toluidine blue staining, and brush biopsy are being integrated into clinical practice, offering non-invasive and efficient diagnostic options. These innovations are crucial in identifying oral lesions at an early stage, thereby enhancing the chances of successful treatment. The growing awareness of oral cancer risks, coupled with advancements in diagnostic methodologies, is expected to drive the demand for oral cancer diagnostics in the coming years.

Regionally, North America holds the largest share of the skin cancer diagnostics market due to high awareness, advanced healthcare infrastructure, and significant investments in research and development. The presence of key market players and favorable reimbursement policies further strengthen the market in this region. Europe follows closely, driven by similar factors and a proactive approach to skin cancer prevention and treatment. The Asia Pacific region is anticipated to witness the fastest growth during the forecast period, attributed to increasing healthcare investments, rising skin cancer incidence, and growing public awareness. Latin America and the Middle East & Africa are also expected to exhibit moderate growth, supported by improving healthcare infrastructure and increased government initiatives.

Diagnostic Type Analysis

The diagnostic type segment of the skin cancer diagnostics market is critical, comprising

The global skin cancer treatment market, valued at $13.82 billion in 2025, is projected to experience robust growth, driven by rising skin cancer incidence rates worldwide, an aging global population increasing susceptibility, and growing awareness regarding early detection and treatment. Technological advancements in diagnostic tools like dermatoscopy and genetic testing, coupled with the development of innovative therapeutic approaches such as immunotherapy and targeted therapy, are significantly contributing to market expansion. The market is segmented by cancer type (melanoma and non-melanoma) and treatment type (diagnosis and therapeutics), with melanoma representing a substantial portion due to its aggressive nature and higher treatment costs. North America currently holds the largest market share, attributed to advanced healthcare infrastructure, high prevalence of skin cancer, and increased spending on healthcare. However, the Asia-Pacific region is expected to witness significant growth in the coming years, driven by rising disposable incomes, increased healthcare awareness, and expanding healthcare infrastructure in developing economies. While effective treatments are available, limitations such as high treatment costs, potential side effects of certain therapies, and lack of access to advanced healthcare in under-resourced regions pose challenges to market growth. The competitive landscape features major pharmaceutical companies and diagnostic providers actively engaged in research and development, further fueling market expansion. The forecast period of 2025-2033 anticipates a continuation of this growth trajectory. The 5.21% CAGR suggests a considerable market expansion, influenced by factors such as ongoing research leading to more targeted and effective treatments, improvements in early detection strategies, and broader access to healthcare in emerging markets. However, the market will continue to navigate challenges like the price sensitivity of certain therapies and the need for sustained investment in research and development to address treatment limitations and enhance patient outcomes. The continued development and adoption of innovative therapies, alongside improvements in diagnostic capabilities, will be key drivers of future market growth. Competition among established players and emerging biotech companies will intensify, further shaping the market landscape in the coming years. Recent developments include: In March 2022, the United States Food and Drug Administration approved nivolumab and relatlimab-rmbw (Opdualag, Bristol-Myers Squibb Company) for adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. Opdualag is a fixed-dose combination of the LAG-3-blocking antibody relatlimab and the programmed death receptor-1 blocking antibody nivolumab., In January 2022, SkinCure Oncology focused on providing a comprehensive model for the delivery of Image-Guided Superficial Radiotherapy (Image-Guided SRT) and launched GentleCure.com, a consumer health education platform offering evidence-based treatment options for basal cell (BCC) and squamous cell skin cancers (SCC).. Key drivers for this market are: Increasing Incidence of Skin Cancer, Rising Awareness About Skin Cancer; Extensive Research and Developments. Potential restraints include: Increasing Incidence of Skin Cancer, Rising Awareness About Skin Cancer; Extensive Research and Developments. Notable trends are: Non-Melanoma by Cancer Type Segment is Expected to Grow Over the Forecast Period.

For current version see: https://data.sandiegocounty.gov/Health/2021-Non-Communicable-Chronic-Diseases/v7dt-rwpx

Basic Metadata *Rates per 100,000 population. Age-adjusted rates per 100,000 2000 US standard population.

**Blank Cells: Rates not calculated for fewer than 5 events. Rates not calculated in cases where zip code is unknown.

***API: Asian/Pacific Islander. ***AIAN: American Indian/Alaska Native.

Prepared by: County of San Diego, Health & Human Services Agency, Public Health Services, Community Health Statistics Unit, 2019.

Code Source: ICD-9CM - AHRQ HCUP CCS v2015. ICD-10CM - AHRQ HCUP CCS v2018. ICD-10 Mortality - California Department of Public Health, Group Cause of Death Codes 2013; NHCS ICD-10 2e-v1 2017.

Data Guide, Dictionary, and Codebook: https://www.sandiegocounty.gov/content/dam/sdc/hhsa/programs/phs/CHS/Community%20Profiles/Public%20Health%20Services%20Codebook_Data%20Guide_Metadata_10.2.19.xlsx

The global skin cancer diagnostics market is experiencing robust growth, driven by rising skin cancer incidence rates worldwide, advancements in diagnostic technologies, and increasing awareness about early detection and prevention. The market's expansion is fueled by the adoption of non-invasive techniques like dermoscopy and advanced imaging modalities such as optical coherence tomography (OCT) and confocal microscopy, offering higher accuracy and faster results compared to traditional biopsy methods. Technological advancements continue to improve the speed, accuracy, and accessibility of skin cancer diagnostics, leading to earlier diagnoses and improved patient outcomes. Furthermore, the growing geriatric population, a key demographic susceptible to skin cancer, is significantly contributing to market expansion. However, high costs associated with advanced diagnostic equipment and procedures, along with regional disparities in healthcare infrastructure and access to advanced technologies, pose challenges to market growth. Segmentation analysis reveals a strong preference for non-invasive techniques across various applications, with a significant portion of the market driven by dermatological clinics and hospitals. The market is witnessing a shift towards personalized medicine approaches, with ongoing research focusing on developing more accurate and targeted diagnostic tools. This includes the development of AI-powered diagnostic systems that can analyze images and provide more precise diagnoses. Geographical analysis shows strong market presence in North America and Europe due to advanced healthcare infrastructure and higher awareness. However, emerging economies in Asia Pacific are exhibiting significant growth potential owing to increasing healthcare spending and rising prevalence of skin cancer. Competitive landscape analysis reveals a mix of established players and emerging companies constantly innovating to enhance their product portfolios and expand their market share. The forecast period (2025-2033) anticipates sustained market growth, propelled by technological innovation and increased accessibility of diagnostic services globally. While challenges remain, the overall outlook for the skin cancer diagnostics market remains positive.

Population based cancer incidence rates were abstracted from National Cancer Institute, State Cancer Profiles for all available counties in the United States for which data were available. This is a national county-level database of cancer data that are collected by state public health surveillance systems. All-site cancer is defined as any type of cancer that is captured in the state registry data, though non-melanoma skin cancer is not included. All-site age-adjusted cancer incidence rates were abstracted separately for males and females. County-level annual age-adjusted all-site cancer incidence rates for years 2006–2010 were available for 2687 of 3142 (85.5%) counties in the U.S. Counties for which there are fewer than 16 reported cases in a specific area-sex-race category are suppressed to ensure confidentiality and stability of rate estimates; this accounted for 14 counties in our study. Two states, Kansas and Virginia, do not provide data because of state legislation and regulations which prohibit the release of county level data to outside entities. Data from Michigan does not include cases diagnosed in other states because data exchange agreements prohibit the release of data to third parties. Finally, state data is not available for three states, Minnesota, Ohio, and Washington. The age-adjusted average annual incidence rate for all counties was 453.7 per 100,000 persons. We selected 2006–2010 as it is subsequent in time to the EQI exposure data which was constructed to represent the years 2000–2005. We also gathered data for the three leading causes of cancer for males (lung, prostate, and colorectal) and females (lung, breast, and colorectal). The EQI was used as an exposure metric as an indicator of cumulative environmental exposures at the county-level representing the period 2000 to 2005. A complete description of the datasets used in the EQI are provided in Lobdell et al. and methods used for index construction are described by Messer et al. The EQI was developed for the period 2000– 2005 because it was the time period for which the most recent data were available when index construction was initiated. The EQI includes variables representing each of the environmental domains. The air domain includes 87 variables representing criteria and hazardous air pollutants. The water domain includes 80 variables representing overall water quality, general water contamination, recreational water quality, drinking water quality, atmospheric deposition, drought, and chemical contamination. The land domain includes 26 variables representing agriculture, pesticides, contaminants, facilities, and radon. The built domain includes 14 variables representing roads, highway/road safety, public transit behavior, business environment, and subsidized housing environment. The sociodemographic environment includes 12 variables representing socioeconomics and crime. This dataset is not publicly accessible because: EPA cannot release personally identifiable information regarding living individuals, according to the Privacy Act and the Freedom of Information Act (FOIA). This dataset contains information about human research subjects. Because there is potential to identify individual participants and disclose personal information, either alone or in combination with other datasets, individual level data are not appropriate to post for public access. Restricted access may be granted to authorized persons by contacting the party listed. It can be accessed through the following means: Human health data are not available publicly. EQI data are available at: https://edg.epa.gov/data/Public/ORD/NHEERL/EQI. Format: Data are stored as csv files. This dataset is associated with the following publication: Jagai, J., L. Messer, K. Rappazzo , C. Gray, S. Grabich , and D. Lobdell. County-level environmental quality and associations with cancer incidence#. Cancer. John Wiley & Sons Incorporated, New York, NY, USA, 123(15): 2901-2908, (2017).

The skin cancer detection devices market size is projected to be worth US$ 959.6 million in 2023. The market is likely to surpass US$ 2.95 billion by 2033 at a CAGR of 11.9% during the forecast period. Growing skin cancer incidences and the awareness regarding skin cancer is aiding the market growth. Since skin cancer affects so many individuals of all ages and ethnicities across the world, the Skin Cancer Foundation and the American Cancer Society urge that everyone should undertake a monthly self-examination of their whole skin surface. The skin cancer gadgets are put to the test with this monthly skin self-examination.

Attributes	Details
Skin Cancer Detection Devices Market Size (2023)	US$ 959.6 million
Skin Cancer Detection Devices Market Projected Size (2033)	US$ 2.95 billion
Value CAGR (2023 to 2033)	11.9%

Country-Wise Insights

Country	The United States
Market Size (US$ million) by End of Forecast Period (2033)	US$ 890.0 million
CAGR % 2023 to End of Forecast (2033)	11.4%

Country	The United Kingdom
Market Size (US$ million) by End of Forecast Period (2033)	US$ 207.0 million
CAGR % 2023 to End of Forecast (2033)	11.6%

Country	China
Market Size (US$ million) by End of Forecast Period (2033)	US$ 285.0 million
CAGR % 2023 to End of Forecast (2033)	13.4%

Country	Japan
Market Size (US$ million) by End of Forecast Period (2033)	US$ 105.0 million
CAGR % 2023 to End of Forecast (2033)	11.2%

Country	South Korea
Market Size (US$ million) by End of Forecast Period (2033)	US$ 59.0 million
CAGR % 2023 to End of Forecast (2033)	12.4%